New Business of Healthcare Interview: Population Health and the New Sales Paradigm

Thursday, May 24, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

"No outcome, no income," says Dr. David Nash in a new Business of Healthcare interview about population health and shared risk contracting. He joins Brad Ansley of SPI Health to explore implications for healthcare suppliers.

CHARLOTTE, N.C., May 24, 2018 /PRNewswire-PRWeb/ -- "No outcome, no income," says Dr. David

Nash, founding dean of Jefferson College of Population Health which is the nation's first graduate school of population health. Nash also serves within Jefferson Health on the Pharmaceutical and Therapeutics Committee and speaks nationally on population health to providers, payers, and physicians.

Brad Ansley of SPI Health joined Dr. Nash for this Business of Healthcare interview exploring the new health system buying process which has emerged with the population health trend. Spoiler alert: it's all about committees instead of individual buyers and comparative effectiveness instead of comparison to placebo.

All of this leads to a new selling dynamic and new expectation for the sales force. "Buyers in the health care marketplace expect you to be the premier expert and understand impact to the organization and individuals along the chain in that organization," says Ansley who has helped hundreds of organizations adapt to the emerging new reality.

Nash wants to see pharma, "be at economic risk with us . . .meaning if we have a readmission, we gotta eat it. If we have a hospital-acquired infection, we gotta eat it. If we chose the wrong antibiotic we've got eat it. If we didn't follow through on the chemotherapy and we didn't describe the side effects and the patient can't go home for two days and on and on."

The trend towards population health has occurred spasmodically and remains uncertain. "I think 10-15% of health system revenue [is exposed to population health risk]," says Nash. "Is it going as fast as David Nash would like it to go? No. But let's put it this way: the research evidence is solid. You want to change clinician behavior, you gotta change the economic incentives. What we need is to involve the specialists, everybody's in on the act. The delivery system is going to get a pot of money and we guys and gals will need to figure it out."

As further proof, Nash points out "It's ten thousand dollars per person in 2017 of health care spending, including children. So, we have to ask ourselves the question getting back to Brad's great comment about value, are we really getting ten grand of value for every person in our family? I have three grown children plus the boss that's five of us so fifty grand. Did we get $50,000 worth of value out of the healthcare system last year? Hardly."

Nash focuses on pharma because, "the best experts believe that 10% [of healthcare spending] is the pharma spend. We're talking a dime or more of every dollar spent so a lot of money is go into pharma."

Ansley believes the shrinking pharma sales force is an indicator of this trend, "Over the past seven years big pharmaceutical sales reps went from 112,000 to 70,000. Now why is that? Because the system has started saying 'I'm receiving no value from the Share of Voice model. In fact, you're taking my time and costing me money.'"

Today, Ansley argues, buyers are saying, 'Show me the evidence and understand my complex sale' which he believes is more closely related to a business-to-business sale as opposed to the single physician decision maker of yesteryear.

"Evidence is a large part of the changing expectation of health care buyers," continues Ansley. "No longer can the sales representative show up with a Fifth Avenue glossy and start talking through their product. The expectation now is that a sales representative speaks the language of evidence-based medicine, statistical significance and clinical relevance and can put that in context of the organization's needs."

"80% of what we do at the bedside, plus or minus two percent, lacks randomized controlled trial evidence," points out Nash. "So let's translate: one out of five decisions we got it nailed. So four out of five, that's the art of medicine. That's expensive and highly variable and, by the way, dangerous."

This lack of evidentiary basis for care helps explain the reluctance to get into the risk bearing. Nash notes, "Are you willing to hang out in a risk environment with us when 80% of the time we're just not sure? I think the reticence is, in part, justified."

What does the future hold? Based on this discussion with Nash and Ansley, one would expect the slow march to value to continue . . . and a radical retooling and retraining for sales organizations serving healthcare.

 

SOURCE Business of Healthcare



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store